Guggenheim Maintains Buy on Compass Therapeutics, Lowers Price Target to $4

Benzinga Newsdesk www.benzinga.com Negative 63.3%

Neg 63.3% Neu 0% Pos 0%

Guggenheim analyst Michael Schmidt maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $8 to $4.